You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2014
|
| DOI | 10.1186/1756-8722-7-1 |
| Pubmed ID | |
| Authors |
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, Adriane M Zernhelt, Daniel M Sullivan, Philippe A Cassier, Eric Chen, Andrea Biondo, Ernestina Tetteh, Lillian L Siu, Amita Patnaik, Kyriakos P Papadopoulos, Johann S de Bono, Anthony W Tolcher, Susan Minton |
| Abstract |
Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 100 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 15% |
| Student > Bachelor | 15 | 15% |
| Student > Master | 14 | 14% |
| Researcher | 10 | 10% |
| Other | 8 | 8% |
| Other | 14 | 14% |
| Unknown | 24 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 27% |
| Biochemistry, Genetics and Molecular Biology | 15 | 15% |
| Agricultural and Biological Sciences | 10 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Engineering | 3 | 3% |
| Other | 12 | 12% |
| Unknown | 28 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2015.
All research outputs
#3,969,578
of 22,739,983 outputs
Outputs from Journal of Hematology & Oncology
#294
of 1,189 outputs
Outputs of similar age
#47,543
of 304,530 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 12 outputs
Altmetric has tracked 22,739,983 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.